Ginkgo Bioworks Holdings (DNA) Short-term Investments (2020 - 2025)
Ginkgo Bioworks Holdings' (DNA) quarterly Short-term Investments came in at $255.4 million in Q4 2025, up 23225.84% on a QoQ basis from $1.1 million in Q2 2023.
Ginkgo Bioworks Holdings (DNA) Short-term Investments (2020 - 2025) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 5 years of Short-term Investments data on file, last reported at $255.4 million in Q4 2025.
- Quarterly Short-term Investments changed N/A year-over-year to $255.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $255.4 million (changed N/A YoY) and the FY2025 annual result came in at $255.4 million, changed N/A from the prior year.
- Short-term Investments rose to $255.4 million in Q4 2025, from $1.1 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $255.4 million in Q4 2025 to a low of $1.1 million in Q2 2023.
- A 4-year average of $33.0 million and a median of $5.5 million in 2022 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2021 — Short-term Investments grew 12.04% — and 2022, when it tumbled 87.38%.
- Tracing DNA's Short-term Investments over 4 years: stood at $15.3 million in 2021, then plunged by 87.38% to $1.9 million in 2022, then tumbled by 43.47% to $1.1 million in 2023, then soared by 23225.84% to $255.4 million in 2025.
- The last three Short-term Investments figures came in at $255.4 million (Q4 2025), $1.1 million (Q2 2023), and $1.6 million (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 255.42 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.61 Mn |
| Dec 31, 2022 | 1.94 Mn |
| Sep 30, 2022 | 2.42 Mn |
| Jun 30, 2022 | 5.50 Mn |
| Mar 31, 2022 | 6.12 Mn |
| Dec 31, 2021 | 15.35 Mn |
| Sep 30, 2021 | 7.66 Mn |
| Dec 31, 2020 | 13.70 Mn |